Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:46:18.888Z.
Calculation as of: 2026-10-06T13:46:18.888Z.
Quote observation: 2026-10-06T13:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3328ed161ff00c537a80d7dceb604f662f1c22c4e65cb57a824bf36ce3bbbe60
PEG RATIO
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $891.36M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $905.71M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $857.50M | N/A | N/A | N/A | N/A |
| Bioventus Inc. (BVS)vs › | $910.80M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $857.82M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $847.84M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $918.01M | 6.51 | 5.08 | 6.65 | 9.17 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $855.78M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $941.50M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $837.98M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute